GRAIL
GRAL
Performance
About GRAIL
GRAIL is a healthcare company focused on detecting cancer earlier using blood-based multi-cancer early detection tests. It develops the Galleri Test and leverages next-generation sequencing, population-scale clinical studies, and advanced data analysis to identify cancer signals before symptoms appear. The company aims to alleviate the global burden of cancer with a mission-driven approach and operates with a focus on early detection across diverse populations in the United States and beyond.
Recent News
Hims Adds Grail's Cancer Test Amid Questions About Widespread Use
Grail Multi-Cancer Test Taps Into Hims & Hers Network
TOBY Gets FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
Grail’s $824 Liquid Biopsy Test Sparks Debate Over Accuracy and Cost
S&P 500 Rises, Dow Gains 200 Points After Supreme Court Strikes Down Trump Emergency Tariffs: Live Updates
Recent Deals
No recent deals for this company.
